JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients

被引:3
作者
Agostini, Simone [1 ]
Mancuso, Roberta [1 ]
Costa, Andrea Saul [1 ]
Caputo, Domenico [1 ]
Clerici, Mario [1 ,2 ]
机构
[1] IRCCS Fdn Don Carlo Gnocchi ONLUS, I-20148 Milan, Italy
[2] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy
来源
VIRUSES-BASEL | 2021年 / 13卷 / 03期
关键词
multiple sclerosis; JCPyV; miRNA; rehabilitation; biomarker;
D O I
10.3390/v13030468
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The use of Natalizumab in Multiple Sclerosis (MS) can cause the reactivation of the polyomavirus JC (JCPyV); this may result in the development of progressive multifocal leukoencephalopathy (PML), a rare and usually lethal disease. JCPyV infection is highly prevalent in worldwide population, but the detection of anti-JCPyV antibodies is not sufficient to identify JCPyV infection, as PML can develop even in patients with negative JCPyV serology. Better comprehension of the JCPyV biology could allow a better understanding of JCPyV infection and reactivation, possibly reducing the risk of developing PML. Here, we investigated whether JCPyV miR-J1-5p-a miRNA that down-regulates the early phase viral protein T-antigen and promotes viral latency-could be detected and quantified by digital droplet PCR (ddPCR) in urine of 25 Natalizumab-treated MS patients. A 24-month study was designed: baseline, before the first dose of Natalizumab, and after 1 (T1), 12 (T12) and 24 months (T24) of therapy. miR-J1-5p was detected in urine of 7/25 MS patients (28%); detection was possible in three cases at T24, in two cases at T12, in one case at T1 and T12, and in the last case at baseline and T1. Two of these patients were seronegative for JCPyV Ab, and viral DNA was never found in either urine or blood. To note, only in one case miR-J1-5p was detected before initiation of Natalizumab. These results suggest that the measurement of miR-J1-5p in urine, could be a biomarker to monitor JCPyV infection and to better identify the possible risk of developing PML in Natalizumab-treated MS patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis
    Kohlmann, Rebekka
    Salmen, Anke
    Chan, Andrew
    Knabbe, Cornelius
    Diekmann, Juergen
    Brockmeyer, Norbert
    Skaletz-Rorowski, Adriane
    Michalik, Claudia
    Gold, Ralf
    Ueberla, Klaus
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (14) : 1823 - 1832
  • [32] JCV detection in multiple sclerosis patients treated with natalizumab
    Sadiq, Saud A.
    Puccio, Lauren M.
    Brydon, Edward W. A.
    JOURNAL OF NEUROLOGY, 2010, 257 (06) : 954 - 958
  • [33] JCV detection in multiple sclerosis patients treated with natalizumab
    Saud A. Sadiq
    Lauren M. Puccio
    Edward W. A. Brydon
    Journal of Neurology, 2010, 257 : 954 - 958
  • [34] Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab
    Dallari, Simone
    Franciotta, Diego
    Carluccio, Silvia
    Signorini, Lucia
    Gastaldi, Matteo
    Colombo, Elena
    Bergamaschi, Roberto
    Elia, Francesca
    Villani, Sonia
    Ferrante, Pasquale
    Delbue, Serena
    JOURNAL OF NEUROIMMUNOLOGY, 2015, 287 : 76 - 79
  • [35] Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis
    Petersen, E. R.
    Sondergaard, H. B.
    Oturai, A. B.
    Jensen, P. E. H.
    Sorensen, P. S.
    Sellebjerg, F.
    Bornsen, L.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 10 : 66 - 72
  • [36] Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
    Sorensen, Per Soelberg
    Jensen, Poul Erik Hyldgaard
    Haghikia, Aiden
    Lundkvist, Malin
    Vedeler, Christian
    Sellebjerg, Finn
    Koch-Henriksen, Nils
    Fogdell-Hahn, Anna
    Myhr, Kjell-Morten
    Hillert, Jan
    Gold, Ralf
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (09) : 1074 - 1078
  • [37] Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients
    Anat Achiron
    Gadi Miron
    Rina Zilkha-Falb
    David Magalashvili
    Mark Dolev
    Yael Stern
    Michael Gurevich
    Journal of NeuroVirology, 2016, 22 : 736 - 746
  • [38] Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients
    Achiron, Anat
    Miron, Gadi
    Zilkha-Falb, Rina
    Magalashvili, David
    Dolev, Mark
    Stern, Yael
    Gurevich, Michael
    JOURNAL OF NEUROVIROLOGY, 2016, 22 (06) : 736 - 746
  • [39] Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients
    Yildiz, Murat
    Tettenborn, Barbara
    Borgwardt, Stefan
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (07) : 902 - 903
  • [40] Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
    Maier, Smaranda
    Simu, Mihaela
    Hutanu, Adina
    Barcutean, Laura
    Voidazan, Septimiu
    Bajko, Zoltan
    Motataianu, Anca
    Lata, Irina
    Balasa, Rodica
    BRAIN SCIENCES, 2020, 10 (11) : 1 - 11